Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of AbGn-168 in psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• AbGn-168 (AbGn-168)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Psoriasis | Phase 1 | Status: COMPLETED